Lecanemab is a monoclonal antibody with high affinity to amyloid-beta soluble protofibrils. It was approved in 2023 as an IV ...

Differences in outcomes between patients with early Alzheimer’s disease who used lecanemab and matched controls increased ...

Four years of lecanemab treatment led to less cognitive decline and potentially even improvement in clinical scores over time, with a favorable safety profile, in the open-label extension trial.

From taking HRT to eating a healthy diet, Kate Muir shares some of the precautionary measures she's trying to avoid ...

Lecanemab and donanemab effects lasting over three years, new treatments, trials of home injections and blood tests for ...

Lecanemab (a.k.a. leqembi) has received full approval from the U.S. Food and Drug Administration. This is the first FDA-approved treatment to help slow the progression of Alzheimer’s disease.

In a large study, experimental drug lecanemab was able to slow down Alzheimer's, but not stop it. Some researchers think the drug will become the first to help many patients; others have questions.

Lecanemab's price may pose another barrier, even with insurance coverage. The drug's maker, Eisai, expects the medicine alone to cost $26,500 a year. Diagnostic and follow-up tests will add to that.

Lecanemab and Aduhelm are part of a class of drugs called monoclonal antibodies, and the agency that oversees Medicare has said it will only pay for this type of Alzheimer’s drug for patients ...

By that point, the lecanemab cohort’s average amyloid level had dropped by 55.48 centiloids and the placebo group had increased by 3.64 centiloids. The confirmatory trial’s results suggest that ...

Lecanemab is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ).

Lecanemab, the new Alzheimer's drug approved by the FDA, is believed by many scientists to be the first to show promise in slowing the progression of dementia. But critics say its rollout will ...